Medication Management in Patients with Elevated Liver Enzymes

Introduction to Medication Management

The American Society of Clinical Oncology recommends that patients with elevated liver enzymes should immediately stop or avoid acetaminophen, NSAIDs, known hepatotoxic drugs, and any unnecessary medications, while infliximab is absolutely contraindicated in immune-related hepatitis 1, 2, 3

The American Gastroenterological Association advises to stop all unnecessary medications and any known hepatotoxic drugs immediately in patients with Grade 2 or higher elevations (AST/ALT >3× ULN) 1, 2, 4
The National Comprehensive Cancer Network recommends temporarily holding other potentially hepatotoxic oncologic agents if the patient is receiving cancer treatment 1, 2
The American Association for the Study of Liver Diseases suggests advising against alcohol consumption and potentially hepatotoxic dietary supplements 4
The American College of Gastroenterology recommends ruling out viral hepatitis, medication-induced injury, and other competing etiologies before attributing elevations to any single cause 1, 2, 4

The American College of Rheumatology states that infliximab is absolutely contraindicated for immune-related hepatitis and should never be used in patients with hepatic immune-related adverse events 1, 2

The American Academy of Clinical Toxicology notes that acetaminophen is the most common cause of drug-induced acute liver failure (15% of all acute liver failure cases, up to 50% of fulminant hepatic failure) and should be avoided or strictly minimized in patients with any signs of liver dysfunction 3
The Infectious Diseases Society of America recommends avoiding acetaminophen during acute hepatitis until resolution of the acute episode 5
The American College of Clinical Pharmacy advises that NSAIDs should be avoided in patients with elevated liver enzymes due to hepatotoxicity risk 6, 3

The National Kidney Foundation recommends reducing methotrexate dose when GFR <60 mL/min/1.73 m² and avoiding if possible when GFR <15 mL/min/1.73 m² 6
The American Academy of Dermatology suggests monitoring liver enzymes closely; if enzymes exceed 5× normal, discontinue the drug 8
The European Association for the Study of the Liver recommends avoiding methotrexate in patients at risk for hepatotoxicity including those with pre-existing liver disease 8

The American Society of Nephrology advises reducing cisplatin dose when GFR <60 mL/min/1.73 m² and avoiding when GFR <30 mL/min/1.73 m² 6
The Infectious Diseases Society of America recommends reducing melphalan dose when GFR <60 mL/min/1.73 m² 6

The American College of Gastroenterology recommends continuing close monitoring with labs 1-2 times weekly for Grade 1 elevations (AST/ALT 1-3× ULN or bilirubin 1-1.5× ULN) 1, 2, 4
The American Association for the Study of Liver Diseases suggests reviewing and stopping unnecessary medications for Grade 1 elevations 2, 4
The American College of Clinical Pharmacy advises stopping unnecessary medications and any known hepatotoxic drugs immediately for Grade 2 elevations (AST/ALT 3-5× ULN or bilirubin 1.5-3× ULN) 1, 2, 4

The American Society of Clinical Oncology warns not to rely solely on laboratory values; serum liver tests may not be abnormal in all instances of hepatotoxicity 3
The American Academy of Clinical Toxicology instructs patients to stop medication immediately if abdominal pain, vomiting, jaundice, or hepatitis symptoms develop 3
The American College of Gastroenterology recommends checking for alternative causes including viral hepatitis, alcohol use, biliary obstruction, hepatic metastases, and thromboembolic events before attributing elevations to medications 1, 2, 4